TBPH · As filed with the SEC
Theravance Biopharma balance sheet, by quarter
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONDENSED CONSOLIDATED BALANCE SHEETS · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 | Q3 2024 Sep 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Current assets: | ||||||||
| Cash and cash equivalents | 219,766,000 | 288,101,000 | 167,806,000 | 174,773,000 | 281,927,000 | 110,614,000 | 37,797,000 | 23,378,000 |
| Short-term marketable securities | 167,891,000 | 106,565,000 | 147,551,000 | 154,907,000 | 56,877,000 | 20,241,000 | 50,553,000 | 67,983,000 |
| Receivables from collaborative arrangements | 20,381,000 | 15,584,000 | 45,539,000 | 18,267,000 | 21,919,000 | 15,353,000 | 18,440,000 | 16,845,000 |
| Receivables from milestones and royalty assets | — | — | 50,000,000 | — | — | — | 50,000,000 | — |
| Prepaid clinical and development services | — | — | — | — | — | — | 73,000 | 597,000 |
| Other prepaid and current assets | 8,624,000 | 7,384,000 | 7,564,000 | 6,750,000 | 5,571,000 | 4,056,000 | 4,204,000 | 7,677,000 |
| Total current assets | 416,662,000 | 417,634,000 | 418,460,000 | 354,697,000 | 366,294,000 | 150,264,000 | 161,067,000 | 116,480,000 |
| Long-term marketable securities | — | — | 11,128,000 | 3,029,000 | — | — | — | — |
| Property and equipment, net | 5,169,000 | 5,539,000 | 5,895,000 | 6,257,000 | 6,641,000 | 7,028,000 | 7,418,000 | 7,788,000 |
| Operating lease assets | 21,926,000 | 23,001,000 | 24,371,000 | 25,450,000 | 26,493,000 | 27,430,000 | 28,354,000 | 29,334,000 |
| Future contingent milestone and royalty assets | — | — | — | 0 | — | 144,200,000 | 144,200,000 | 194,200,000 |
| Restricted cash | 836,000 | 836,000 | 836,000 | 836,000 | 836,000 | 836,000 | 836,000 | 836,000 |
| Other assets | 25,177,000 | 25,303,000 | 24,880,000 | 25,191,000 | 25,771,000 | 13,824,000 | 12,286,000 | 7,467,000 |
| Total assets | 469,770,000 | 472,313,000 | 485,570,000 | 415,460,000 | 426,035,000 | 343,582,000 | 354,161,000 | 356,105,000 |
| Current liabilities: | ||||||||
| Accounts payable | 652,000 | 1,100,000 | 2,568,000 | 2,213,000 | 1,675,000 | 2,408,000 | 2,242,000 | 1,454,000 |
| Accrued personnel-related expenses | 7,825,000 | 8,730,000 | 12,592,000 | 10,330,000 | 7,259,000 | 5,386,000 | 7,019,000 | 7,842,000 |
| Accrued clinical and development expenses | 2,395,000 | 2,396,000 | 3,373,000 | 5,842,000 | 3,783,000 | 2,457,000 | 1,058,000 | 864,000 |
| Accrued general and administrative expenses | 8,816,000 | 2,522,000 | 2,052,000 | 2,699,000 | 2,459,000 | 2,520,000 | 2,987,000 | 1,379,000 |
| Operating lease liabilities | 10,795,000 | 10,752,000 | 10,945,000 | 10,914,000 | 10,896,000 | 10,807,000 | 10,712,000 | 4,196,000 |
| Income tax payable | — | 5,287,000 | 5,287,000 | 4,074,000 | 26,696,000 | 5,853,000 | 5,853,000 | — |
| Other accrued liabilities | 283,000 | 988,000 | 1,485,000 | 1,335,000 | 1,865,000 | 2,071,000 | 2,214,000 | 1,210,000 |
| Tenant improvement payable to sublessee | — | — | — | — | — | — | — | 6,490,000 |
| Total current liabilities | 30,766,000 | 31,775,000 | 38,302,000 | 37,407,000 | 54,633,000 | 31,502,000 | 32,085,000 | 23,435,000 |
| Long-term operating lease liabilities | 27,774,000 | 29,752,000 | 31,758,000 | 33,681,000 | 35,561,000 | 37,349,000 | 39,108,000 | 40,785,000 |
| Future royalty payment contingency | 32,795,000 | 32,795,000 | 32,795,000 | 32,213,000 | 31,640,000 | 30,977,000 | 30,334,000 | 29,691,000 |
| Unrecognized tax benefits | — | — | — | 79,165,000 | 77,805,000 | 76,484,000 | 75,199,000 | 71,563,000 |
| Unrecognized tax benefits | 88,486,000 | 87,153,000 | 85,679,000 | — | — | — | — | — |
| Other long-term liabilities | 244,000 | 244,000 | 313,000 | 313,000 | 1,548,000 | 1,287,000 | 1,890,000 | 4,977,000 |
| Shareholders' Equity | ||||||||
| Ordinary shares, $0.00001 par value per share: 200,000 shares authorized; 51,891 and 51,069 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | 1,000 | — | — |
| Additional paid-in capital | 1,160,238,000 | 1,155,215,000 | 1,156,288,000 | 1,153,299,000 | 1,149,123,000 | 1,145,083,000 | 1,141,060,000 | 1,135,599,000 |
| Accumulated other comprehensive income (loss) | (76,000) | (62,000) | 61,000 | 32,000 | (10,000) | — | 7,000 | 50,000 |
| Accumulated deficit | (870,458,000) | (864,560,000) | (859,627,000) | (920,651,000) | (924,266,000) | (979,101,000) | (965,522,000) | (949,995,000) |
| Total shareholders' equity | 289,705,000 | 290,594,000 | 296,723,000 | 232,681,000 | 224,848,000 | 165,983,000 | 175,545,000 | 185,654,000 |
| Total liabilities and shareholders' equity | 469,770,000 | 472,313,000 | 485,570,000 | 415,460,000 | 426,035,000 | 343,582,000 | 354,161,000 | 356,105,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.
Data on this page was fetched . The filing on SEC.gov is the record.